Cell cycle aberrations in Alzheimer's disease: A novel therapeutic opportunity

Expert Review of Neurotherapeutics

Volumn 9, Issue 11, 2009, Pages 1579-1580

  Snape, Mike ^a   Lee, Hyoung Gon ^b   Casadesus, Gemma ^c   Smith, Mark A ^b  

^a Fetcham Leatherhead   (United Kingdom)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; EPIGALLOCATECHIN GALLATE; TAMOXIFEN; TAU PROTEIN; VALPROIC ACID;

ALZHEIMER DISEASE; CELL CYCLE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEMENTIA; EDITORIAL; FUNCTIONAL STATUS; HUMAN; NERVE DEGENERATION; NONHUMAN; ONCOGENE C MYC; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANIMALS; CELL CYCLE; HUMANS;

EID: 70849130982     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.113     Document Type: Editorial

References (14)

1. Smith MA. Alzheimer disease. Int. Rev. Neurobiol. 42, 1-54 (1998).
2. Smith MA, Casadesus G. Walking toward a convergence in aging research. Front. Neurosci. 3(1), 1 (2009).
3. Marlatt MW, Webber KM, Moreira PI et al. Therapeutic opportunities in Alzheimer disease: one for all or all for one? Curr. Med. Chem. 12(10), 1137-1147 (2005).
4. Loveman E, Green C, Kirby J et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol. Assess. 10(1), iii-iv ix-xi 1-160 (2006).
5. Bowser R, Smith MA. Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J. Alzheimers Dis. 4(3), 249-254 (2002).
6. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3(4), 219-226 (2004).
7. Lee HG, Casadesus G, Zhu X et al. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem. Int. 54(2), 84-88 (2009).
8. McShea A, Lee HG, Petersen RB et al. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim. Biophys. Acta 1772(4), 467-472 (2007).
9. Lee HG, Casadesus G, Nunomura A et al. The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am. J. Pathol. 174(3), 891-897 (2009).
10. Woods J, Snape M, Smith MA. The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development. Biochim. Biophys. Acta 1772(4), 503-508 (2007).
11. Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated c-MYC expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathol. Appl. Neurobiol. 27(5), 343-351 (2001).
12. Breuer B, Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health 31(1), 71-85 (2000).
13. Clinical trials database. Identifier: NCT00951834 http://clinicaltrials. gov/ct2/show/NCT00951834
14. Clinical trials database. Identifier: NCT00071721 http://clinicaltrials. gov/ct2/show/NCT00071721